Skip to main content
Andrew J. Yee, MD, Oncology, Boston, MA

Andrew J.YeeMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center

Join to view full profile

Dr. Yee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Yee's full profile

Already have an account?

  • Office

    55 Fruit St
    Yawkey 9A
    Boston, MA 02114
    Phone+1 617-724-4000

Summary

  • Dr. Andrew J. Yee is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and North Shore Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School and has been in practice 17 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
  • Harvard Medical School
    Harvard Medical SchoolClass of 2000

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2002 - 2026
  • NH State Medical License
    NH State Medical License 2009 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Analysis of Hospitalization and Readmissions after CAR T Cell Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Professional Memberships

Dr. Andrew J. Yee, Dr. Andrew J. Yee, MD, Dr. A Yee